ImmunityBio, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$113M
Cost of Revenue
$753K
R&D
$190M
SG&A
$169M
D&A
$16M
Operating Income
$-256M
EBITDA
$-241M
Interest Expense
$61M
Interest Income
—
Other Income/Expense
$-35M
Pretax Income
$-352M
Tax Provision
$-135K
Net Income
$-351M
Operating Margin
-226.0%
Net Margin
-310.2%
Effective Tax Rate
0.0%
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$856M
Tax Credit Carryforwards
$74M
NOL Carryforwards
$567M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
-0.2%
Operating Lease Cost
$11M
Revenue YoY Variation
668.3%
Income YoY Variation
25.6%